Fee increases will finance new Indian regs authority
This article was originally published in Clinica
Executive Summary
Fees from healthcare companies would be the sole source of funding for the Central Drug Authority (CDA) proposed by India's ministry of health in its drugs and cosmetics amendment bill (see Clinica 1300, p 13). The finance ministry and planning commission have ruled out budgetary support for the new authority.